Open AccessImpact of vitamin E on plasma asymmetric dimethylarginine (ADMA) in chronic kidney disease (CKD): a pilot study
Author(s) -
Rajiv Saran,
James E. Novak,
Anjali Desai,
Emil Abdulhayoglu,
Jeffrey S. Warren,
Rami Bustami,
Garry J. Handelman,
Damian Barbato,
William F. Weitzel,
Louis G. D’Alecy,
Sanjay Rajagopalan
Publication year - 2003
Publication title -
nephrology dialysis transplantation
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 1.654
H-Index - 168
eISSN - 1460-2385
pISSN - 0931-0509
DOI - 10.1093/ndt/gfg406
Subject(s) - medicine , asymmetric dimethylarginine , kidney disease , vitamin d and neurology , endocrinology , arginine , biochemistry , chemistry , amino acid
Asymmetric dimethylarginine (ADMA), an endogenous inhibitor of endothelial nitric oxide synthase and a proposed cardiovascular risk factor, is elevated in chronic kidney disease (CKD). Pharmacological strategies that lower plasma concentration of ADMA may be expected to increase nitric oxide (NO.) bioavailability and potentially limit atherosclerosis. We hypothesized that the antioxidant alpha-tocopherol (vitamin E) reduces ADMA levels in CKD.
Accelerating Research
Robert Robinson Avenue,
Oxford Science Park, Oxford
OX4 4GP, United Kingdom
Address
John Eccles HouseRobert Robinson Avenue,
Oxford Science Park, Oxford
OX4 4GP, United Kingdom